PRECIPIO INC
PRPONASDAQTrading Snapshot
- Day Range
- $23.21 – $23.69
- 52-Week Range
- $16.40 – $33.63
- Volume
- $3.43B
- Avg Volume
- $4.00B
- Shares Outstanding
- 1.8M
- Next Earnings
- Nov 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $24M
- Last Q Revenue
- $7M
- P/E Ratio
- -37.1
- P/S Ratio
- 1.6x
- EPS (TTM)
- $-0.68
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +7.5%
Why Investors Own PRPO
- ✓High-growth profile — revenue up +44.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PRECIPIO INC
PRPO
StockOtter · stockotter.spaceAbout PRECIPIO INC
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.
Analyzing Precipio (NASDAQ:PRPO) and AdaptHealth (NASDAQ:AHCO)
AdaptHealth (NASDAQ: AHCO - Get Free Report) and Precipio (NASDAQ: PRPO - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Precipio Announces Q2-2026 Financial Results
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash positio